Cost-effectiveness of a health intervention program with risk reductions for getting demented: Results of a Markov model in a Swedish/Finnish setting

Journal of Alzheimer's Disease

Volumn 26, Issue 4, 2011, Pages 735-744

  Zhang, Yanlei ^a,b   Kivipelto, Miia ^a,c   Solomon, Alina ^a,c   Wimo, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Cost and cost analysis; dementia; economics; risk; risk reduction behavior

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEMENTIA; FINLAND; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SWEDEN;

EID: 80055052615     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110065     Document Type: Article

References (41)

1. WHO (2010) The European Health report 2009, Health and health systems. 2010.
2. Wimo A, Prince M.World Alzheimer report 2010. The global economic impact of dementia.
3. SBU (2008) Dementia. A systematic review. Stockholm. Statens beredning för medicinsk utvärdering (SBU) (The Swedish Council on Technology Assessment in Health Care). Report No.: 172E/1-3.
4. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimers disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342. (Pubitemid 28402270)
5. Jorm AF, Dear KB, Burgess NM (2005) Projections of future numbers of dementia cases in Australia with and without prevention. Aust N Z J Psychiatry 39, 959-963. (Pubitemid 43904431)
6. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J (2006) Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 5, 735-741. (Pubitemid 44205512)
7. Skoog I (2000) Vascular aspects in Alzheimers disease. J Neural Transm Suppl 59, 37-43.
8. Aguero-Torres H, Kivipelto M, von Strauss E (2006) Rethinking the dementia diagnoses in a population-based study: what is Alzheimers disease and what is vascular dementia?Astudy from the Kungsholmen project. Dement Geriatr Cogn Disord 22, 244-249. (Pubitemid 44310521)
9. Wheeler MT, Heidenreich PA, Froelicher VF, Hlatky MA, Ashley EA (2010) Cost-effectiveness of preparticipation screening for prevention of sudden cardiac death in young athletes. Ann Intern Med 152, 276-286.
10. Bellomo A, Mancinella M, Troisi G, Marigliano V (2009) Relationship between atrial fibrillation and other cardiovascular risk factors in Alzheimers disease. New prevention opportunities. Recenti Prog Med 100, 124-126.
11. Jacobs-van der Bruggen MA, van Baal PH, Hoogenveen RT, Feenstra TL, Briggs AH, Lawson K, Feskens EJ, Baan CA (2009) Cost-effectiveness of lifestyle modification in diabetic patients. Diabetes Care 32, 1453-1458.
12. National Institutes of Health. NIH State-of-the-Science Conference Statement on Preventing Alzheimers disease and Cognitive Decline database on the Internet]. National institutes of health (NIH) 2010 Available from: http://consensus. nih.gov/2010/docs/alz/ALZ Final Statement.pdf.
13. Ahtiluoto S, Ngandu T, Rauramaa R, Soininen H, Laatikainen T, Sulkava R, Strandberg T, Tuomilehto J, KivipeltoM(2010) Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) (abstract). 10th International Conference of Alzheimers Disease (ICAD); 2010; Honolulu, USA 2010.
14. FINGER. (in Finnish) 2010 updated 2010]; Available from: http://www.thl.fi/fi FI/web/fi/tutkimus/hankkeet/finger.
15. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, Vray M (1997) Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6, 217-227. (Pubitemid 27296586)
16. Gustavsson A, Jonsson L, Fillit H, Johansson G, Wimo A, Winblad B (2010) IPECAD5-Fifth International Pharmaco-Economic Conference on Alzheimers Disease. J Nutr Health Aging 14, 358-360.
17. Wimo A, Winblad B (2004) Economic aspects on drug therapy of dementia. Curr Pharm Design 10, 295-301. (Pubitemid 38072764)
18. ZhangYL(2010) Potential cost-effectiveness of a health intervention program with risk reductions for being demented. Department of Public Health Sciences, Karolinska Intstitutet, Stockholm, Sweden.
19. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, Lobo A, Martinez-Lage J, Soininen H, Hofman A (2000) Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11 Suppl 5), S10-S15. (Pubitemid 30390599)
20. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Alzheimers disease international. Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2217.
21. Hofman A, Rocca WA, Brayne C, Breteler MM, Clarke M, Cooper B, Copeland JR, Dartigues JF, da Silva Droux A, Hagnell O, et al. (1991) The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol. 20, 736-748.
22. Jorm AF, Korten AE, Henderson AS (1987) The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 76, 465-479. (Pubitemid 17164786)
23. Deaths by region, age (the year of birth) and sex database on the Internet]. Statistiska Centralbyran SCB (statistics Sweden). 2010 Accessed 2010-03-14]. Available from: http://www.ssd.scb.se.
24. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B (1999) Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J Clin Epidemiol 52, 737-743. (Pubitemid 29361449)
25. Wimo A, Johansson L, Joumlnsson L. Demenssjukdomarnas samhällskostnader och antalet dementa i Sverige 2005 (The societal costs of dementia and the number of demented in Sweden 2005) (in Swedish). Stockholm: Socialstyrelsen; 2007. Report No.: 2007-123-32.
26. Wimo A, Johansson L, Jonsson L (2009) Prevalence study of societal costs for dementia 2000-2005. More demented people-but somewhat reduced costs per person (abstract in English). Lakartidningen 106, 1277-1282.
27. Lindholm L, Rosen M, Weinehall L, Asplund K (1996) Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjo, Sweden. J Epidemiol Community Health 50, 190-195.
28. Richard JL (1988) The MONICA project. A WHO research project in cardiovascular diseases]. Rev Epidemiol Sante Publique 36, 325-334. (Pubitemid 19022160)
29. SBU. Måttligt förhöjt blodtryck, volym 1 (2004) En systematisk litteraturöversikt (Moderate increased blood pressure. Volyme 1. A systematic literature review) (in Swedish). Statens beredning för medicinsk utvärdering (SBU) (The Swedish Council on Technology Assessment in Health Care), Stockholm.
30. Läkemedelsverket (2009) (Swedish Medical Products Agency). Läkemedelsboken 2009-2010 (in Swedish). Stockholm.
31. Centrum För Folkhälsa (2009) Diabetes i Stockholms län: förekomst och tidstrender (Diabetes in the county council of Stockholm: occurrence and time trends) (in Swedish). Stockholm: Epidemiologiska enheten, Centrum för, Folkhälsa, Stockholms läns landsting och Diabetespreventiva enheten, Karolinska Universitetsjukuset.
32. Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10, 621-635. (Pubitemid 34056332)
33. Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jonsson L (2010) Cross sectional observational study on the societal costs of Alzheimers disease. Curr Alzheimer Res 7, 358-367.
34. Briggs AH, Gray AM (1999) Handling uncertainty in economic evaluations of healthcare interventions. BMJ 319, 635-638. (Pubitemid 29414568)
35. TLV (2009) (The Dental and Pharmaceutical Benefits Agency). Tillägg till uppdrag angående förberedande åtgärder med anledning av omregleringen av apoteksmarknaden (Addition to comission regarding preparatory actions because of the reregulation of the pharmaceutical market) (in Swedish). Stockholm.
36. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM (2003). SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24, 987-1003.
37. Barnes DE, Covinsky KE, Whitmer RA, Kuller LH, Lopez OL, Yaffe K (2009) Predicting risk of dementia in older adults: The late-life dementia risk index. Neurology 73, 173-179.
38. Whitmer R, Barnes D, Kivipelto M, Ngandu T, Yaffe K, editors (2007) Validation and development of the midlife dementia risk score in the Kaiser Permanente Population (abstract). Gerontological Society of America Annual Scientific Meeting. San Francisco.
39. Nordberg G, Wimo A, Jönsson L, Kåreholt I, Sjölund BM, Lagergren M, von StraussE(2007)Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen project-a population based study in Sweden. Int J Geriatric Psychiatry 22, 639-648. (Pubitemid 47180376)
40. Wimo A, Johansson L, LJ (2009) Prevalence study of societal costs for dementia 2000-2005. More demented people-but somewhat reduced costs per person (in Swedish)]. Lakartidningen 106, 1277-1282.
41. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR (1997) Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics. 11, 159-168. (Pubitemid 27086806)